Ch. 4 Cultural, Legal, Ethical Flashcards
A type of warning that appears in a drug’s prescribing information and is required by the U.S. Food and Drug Administration (FDA) to alert prescribers of serious adverse events that have occurred with the given drug.
Black box warning
Any systematic error in a measurement process. One common effort to avoid bias in research studies involves the use of blinded study designs (see later).
Bias
A research design in which the subjects are purposely unaware of whether the substance they are administered is the drug under study or a placebo. This method serves to minimize bias on the part of research subjects in reporting their body’s responses to investigational drugs
Blinded investigational drug study
Any drugs listed on one of the “schedules” of the Controlled Substance Act (also called scheduled drugs).
Controlled substances
The customary beliefs, social forms, and material traits of a racial, religious, or social group.
Culture
A research design in which both the investigator(s) and the subjects are purposely unaware of whether the substance administered to a given subject is the drug under study or a placebo. This method minimizes bias on the part of both the investigator and the subject
Doubled- blind investigational drug study
Variation in response to a drug because of a patient’s age, gender, size, and/or body composition.
Drug polymorphism
The rules of conduct recognized in respect to a particular class of human actions or a particular group.
Ethics
Relating to or characteristics of a human group having racial, religious, language, and other traits in common.
Ethnicity
The study of the effect of ethnicity on drug responses, specifically drug absorption, metabolism, distribution, and excretion (i.e., pharmacokinetics; see Chapter 2) as well as the study of genetic variations to drugs (i.e., pharmacogenetics).
Ethnopharmacology
Acceleration of the usual investigational new drug approval process by the FDA and pharmaceutical companies, usually for drugs used to treat life-threatening diseases.
Expedited drug approval
An act that protects health insurance coverage for workers and their families when they change jobs. It also protects patient information. If confidentiality of a patient is breached, severe fines may be imposed.
Health insurance portability and accountability act (HIPAA)
Written permission obtained from a patient consenting to a specific procedure (e.g., receiving an investigational drug), after the patient has been given information regarding the procedure deemed necessary for him or her to make a sound or “informed” decision.
Informed consent
A drug not yet approved for marketing by the FDA but available for use in experiments to determine its safety and efficacy.
Investigational new drug (IND)
An application that must be submitted to the FDA before a drug can be studied in humans.
Investigational new drug application